Earnings Call Summary | Dentsply Sirona(XRAY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Dentsply Sirona(XRAY.US) Q1 2024 Earnings Conference
The following is a summary of the DENTSPLY SIRONA Inc. (XRAY) Q1 2024 Earnings Call Transcript:
以下是DENTSPLY SIRONA Inc.（XRAY）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
DENTSPLY SIRONA reported Q1 2024 revenue of $953 million, a decline of 2.6% from the prior year quarter.
Gross margin remained stable year-over-year but improved sequentially by 140 basis points.
Adjusted EPS was $0.42 in Q1, reflecting an 8% increase over the previous year.
Due to macroeconomic uncertainties influencing the imaging business, the full-year outlook for organic sales and adjusted EPS trends towards the lower end of the range.
A share repurchase of up to $150 million is planned for Q2 2024.
DENTSPLY SIRONA公佈的2024年第一季度收入爲9.53億美元，比上一季度下降2.6％。
毛利率同比保持穩定，但連續增長了140個點子。
第一季度調整後的每股收益爲0.42美元，比上年增長8％。
由於宏觀經濟的不確定性影響了影像業務，全年有機銷售前景以及調整後的每股收益趨勢均接近該區間的低端。
計劃在2024年第二季度進行高達1.5億美元的股票回購。
Business Progress:
業務進展：
To support business growth, DENTSPLY SIRONA continues prioritizing product innovation, supply chain transformation, SKU optimization, and data/AI strategy.
Recovery strategies include reintroducing Orthophos SL, launching Axano Pure, and growing DS Core adoption.
Expanding in high-growth categories such as orthodontics and implants is a strategic focus.
Sustainability initiatives and improving equitable access to oral healthcare form part of the company's commitment.
Despite expected challenges in 2024, growth is expected in 2025 and the company aims to achieve a $3 target for EPS by 2026.
Efforts are ongoing to grow the Byte business and enhancements are being made in restructuring strategies, product offerings in Wellspect, and SKU rationalization efforts.
爲了支持業務增長，DENTSPLY SIRONA繼續優先考慮產品創新、供應鏈轉型、SKU優化和數據/人工智能戰略。
恢復策略包括重新引入Orthophos SL、推出Axano Pure以及提高DS Core的採用率。
擴大正畸和植入物等高增長類別是戰略重點。
可持續發展舉措和改善公平獲得口腔醫療保健的機會是公司承諾的一部分。
儘管預計2024年將面臨挑戰，但預計將在2025年實現增長，該公司的目標是到2026年實現每股收益3美元的目標。
正在努力發展Byte業務，並正在加強重組戰略、Wellspect的產品供應和SKU合理化工作。
More details: Dentsply Sirona IR
更多詳情： Dentsply Sirona IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。